How did the Pro Medicus (ASX:PME) share price respond last earnings season?

Pro Medicus’ FY21 earnings are imminent. While we wait, let’s take a look at how its shares reacted to its FY20 results
The post How did the Pro Medicus (ASX:PME) share price respond last earnings season? appeared first on The Motley Fool Australia. –

The Pro Medicus Limited (ASX: PME) share price has had a brilliant 12 months on the ASX, and all eyes will be on it tomorrow when the company drops its results for financial year 2021 (FY21).

Since this time last year, the Pro Medicus share price has gained a whopping 136%. For comparison, the S&P/ASX 200 Index (ASX: XJO) increased 24% in the same time frame. However, Pro Medicus shares have dipped by 0.12% in early trade today.

Market watchers will likely be particularly curious about Pro Medicus’ earnings since the company’s stock hit its highest closing price of all time just over a month ago.

So, as the market awaits the healthcare imaging company’s FY21 earnings, lets cast our minds back to its FY20 results and how the Pro Medicus share price reacted.

How did Pro Medicus perform in FY20?

The market wasn’t excited about Pro Medicus’ FY20 earnings, despite the company’s performance being relatively strong. Here’s a sample of Pro Medicus’ FY20 results:

$56.8 million of revenue from underlying operations, 23.9% more than the prior corresponding period
Underlying profit before tax increased 33.4% to $30.24 million, excluding a capital sale from the previous period
$23.1 million worth of full-year reported profits, a 20.7% increase
$43.4 million worth of cash in the bank and no debt
A 6-cent final dividend, bringing its total FY20 dividends to 12 cents per share

Pro Medicus’ growth was driven by increases in its transaction revenues in North America and Australia.

However, the company’s European revenue dropped, mainly because the company completed a $3 million one-off capital sale to the German government in FY19.

The Pro Medicus share price dipped on the back of its FY20 results. It ended the day 2.5% lower than where it started.

What’s driven the Pro Medicus share price since?

Pro Medicus has been performing brilliantly on the ASX since it dropped its FY20 earnings.

It has announced a seven-year contract and research agreement with NYU Langone Health, a $10 million deal with LMU Klinikum, a five-year contract with MedStar Health, and a seven-year contract with Intermountain Healthcare.

Additionally, Pro Medicus announced a new on-market share buyback in April. The buyback will see it pocketing 10% of its issued securities.

With so much productivity evidenced in the company’s market releases during FY21, investors may be on the edge of their seat waiting to see how the Pro Medicus share price responds to its imminent results.

At its current share price, Pro Medicus has a market capitalisation of around $5.92 billion. It has approximately 104 million shares outstanding.

The post How did the Pro Medicus (ASX:PME) share price respond last earnings season? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Pro Medicus right now?

Before you consider Pro Medicus, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

The best and worst performing ASX 200 healthcare shares of 2021

Pro Medicus (ASX:PME) share price tumbles 5% on broker downgrade
Why Fortescue, Over The Wire, Pro Medicus, & Whispir shares are dropping

ASX 200 midday update: Afterpay to be acquired by Square, Oil Search to merge with Santos

5 things to watch on the ASX 200 on Monday

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!